Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
International Journal of Molecular Sciences|November 14, 2023
Global Proteomics for Identifying the Alteration Pathway of Niemann-Pick Disease Type C Using Hepatic Cell ModelsKeitaro Miyoshi, Eiji Hishinuma, Naomi Matsukawa, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 14, 2014
Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapyXiangru Li, Manami Iida, Minoru Tada, et al.
Pharmacology Research & Perspectives|October 8, 2016
Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibodyYosuke Hashimoto, Yumi Kawahigashi, Tomoyuki Hata, et al.
Journal of Virology|June 6, 2014
Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cellsPil Soo Sung, Asako Murayama, Wonseok Kang, et al.
Scientific Reports|November 24, 2022
A single mutation in the E2 glycoprotein of hepatitis C virus broadens the claudin specificity for its infectionYoshitaka Shirasago, Hidesuke Fukazawa, Shotaro Nagase, et al.
International Journal of Molecular Sciences|January 8, 2023
Direct Inhibition of SARS-CoV-2 Spike Protein by Peracetic AcidYuichiro Yamamoto, Yoshio Nakano, Mana Murae, et al.
Journal of Molecular Biology|June 22, 2026
Allosteric targeting of the ACE2 dimer interface by a medium-sized compound inhibits SARS-CoV-2 entryMariko Yokogawa, Shunki Kaneichi, Mahoro Horiuchi, et al.
Journal of Virology|March 28, 2008
Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infectionHideki Aizaki, Kenichi Morikawa, Masayoshi Fukasawa, et al.
BMC Cancer|June 27, 2018
Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cellsYuko Murakami, Kazuo Sugiyama, Hirotoshi Ebinuma, et al.
Pageof 8